- Home
- SEER vs CCCC Comparison
SEER vs CCCC Comparison
Compare SEER & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- CCCC
- Stock Information
- Founded
- SEER 2017
- CCCC 2015
- Country
- SEER United States
- CCCC United States
- Employees
- SEER 134
- CCCC N/A
- Industry
- SEER Medicinal Chemicals and Botanical Products
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- SEER Health Care
- CCCC Health Care
- Exchange
- SEER Nasdaq
- CCCC Nasdaq
- Market Cap
- SEER 121.8M
- CCCC 115.0M
- IPO Year
- SEER 2020
- CCCC 2020
- Fundamental
- Price
- SEER $1.84
- CCCC $1.47
- Analyst Decision
- SEER Hold
- CCCC Buy
- Analyst Count
- SEER 1
- CCCC 4
- Target Price
- SEER $3.00
- CCCC $12.50
- AVG Volume (30 Days)
- SEER 174.6K
- CCCC 1.3M
- Earning Date
- SEER 05-13-2025
- CCCC 05-07-2025
- Dividend Yield
- SEER N/A
- CCCC N/A
- EPS Growth
- SEER N/A
- CCCC N/A
- EPS
- SEER N/A
- CCCC N/A
- Revenue
- SEER $14,170,000.00
- CCCC $39,783,000.00
- Revenue This Year
- SEER $23.54
- CCCC N/A
- Revenue Next Year
- SEER $42.98
- CCCC $36.31
- P/E Ratio
- SEER N/A
- CCCC N/A
- Revenue Growth
- SEER N/A
- CCCC 98.56
- 52 Week Low
- SEER $1.56
- CCCC $1.09
- 52 Week High
- SEER $2.63
- CCCC $7.66
- Technical
- Relative Strength Index (RSI)
- SEER 41.77
- CCCC 44.60
- Support Level
- SEER $1.88
- CCCC $1.42
- Resistance Level
- SEER $1.97
- CCCC $1.69
- Average True Range (ATR)
- SEER 0.10
- CCCC 0.16
- MACD
- SEER -0.02
- CCCC 0.03
- Stochastic Oscillator
- SEER 0.00
- CCCC 27.27
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.